Nicox S.A. (OTCMKTS:NICXF – Get Rating) – Equities research analysts at HC Wainwright lowered their Q1 2023 earnings per share (EPS) estimates for Nicox in a research note issued to investors on Wednesday, April 19th. HC Wainwright analyst R. Selvaraju now expects that the company will post earnings of ($0.13) per share for the quarter, down from their previous forecast of ($0.12). The consensus estimate for Nicox’s current full-year earnings is ($0.76) per share. HC Wainwright also issued estimates for Nicox’s Q2 2023 earnings at ($0.13) EPS, FY2023 earnings at ($0.52) EPS and FY2024 earnings at ($0.43) EPS.
Nicox Price Performance
Shares of OTCMKTS:NICXF opened at $0.64 on Monday. Nicox has a 12-month low of $0.64 and a 12-month high of $0.89. The business’s 50 day moving average is $0.74 and its 200 day moving average is $1.14.
About Nicox
Nicox SA is an ophthalmology company. The firm engages in developing solutions to help maintain vision and improve ocular health. Its products include Zerviate and Vyzulta. The company was founded by Piero Del Soldato, Michele Garufi and Elizabeth Marie Robinson on February 15, 1996 and is headquartered in Sophia-Antipolis, France.
Recommended Stories
- Get a free copy of the StockNews.com research report on Nicox (NICXF)
- MarketBeat Week in Review – 4/17 – 4/21
- 2 Industrial Strength Dividend Stocks Melting Up
- Proctor & Gamble Is Going To Set A New High
- AutoNation’s Plans are Keeping Analysts Around
- Netflix Increases Buybacks: Can It Complete A Reversal In 2023?
Receive News & Ratings for Nicox Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nicox and related companies with MarketBeat.com's FREE daily email newsletter.
